Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Will AbbVie's Oncology Franchise Weigh on Q1 Top-line Growth?
AbbVie (ABBV) is expected to report first-quarter 2026 results soon, with its oncology franchise likely to face headwinds due to declining Imbruvica sales and pricing pressures, potentially impacting overall revenue growth. While newer cancer therapies and other drugs are contributing, Imbruvica’s continued sales erosion is a significant concern for the oncology segment. The company’s stock has underperformed its industry year-to-date and trades at a discount based on P/E ratio, with EPS estimates for 2026 and 2027 having declined recently.